modelDidanosine
Extends from Pharmacolibrary.Drugs.ATC.J.J05AF02.
Information
| name: | Didanosine | |
| ATC code: | J05AF02 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 0.96 | L |
| clearance: | 15.9 | L/h |
| other parameters in model implementation | ||
Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of human immunodeficiency virus (HIV) infection. It inhibits viral replication by interfering with viral reverse transcriptase. Didanosine was widely used in HIV therapy but its use has declined due to the availability of better-tolerated alternatives and concerns about toxicity. It is still used today in some settings, although less frequently.
Pharmacokinetics
Pharmacokinetic parameters reported for adult HIV-infected patients following single oral doses of didanosine 200 mg (fasting state).
References
Zhou, XJ, et al., & Sommadossi, JP (1999). Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial agents and chemotherapy 43(1) 121–128. DOI:10.1128/AAC.43.1.121 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9869576
Velasque, LS, et al., & Struchiner, CJ (2007). A new model for the population pharmacokinetics of didanosine in healthy subjects. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 40(1) 97–104. DOI:10.1590/s0100-879x2007000100013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17225002
Kearney, BP, et al., & Shah, J (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics 43(9) 595–612. DOI:10.2165/00003088-200443090-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15217303
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)